[go: up one dir, main page]

TNSN06025A1 - Mélanges d'oligosaccharides dérivés d'heparine, leur préparation et les compositions pharmaceutiques les contenant - Google Patents

Mélanges d'oligosaccharides dérivés d'heparine, leur préparation et les compositions pharmaceutiques les contenant

Info

Publication number
TNSN06025A1
TNSN06025A1 TNP2006000025A TNSN06025A TNSN06025A1 TN SN06025 A1 TNSN06025 A1 TN SN06025A1 TN P2006000025 A TNP2006000025 A TN P2006000025A TN SN06025 A TNSN06025 A TN SN06025A TN SN06025 A1 TNSN06025 A1 TN SN06025A1
Authority
TN
Tunisia
Prior art keywords
les
dérivés
oligosaccharides
mélanges
contenant
Prior art date
Application number
TNP2006000025A
Other languages
French (fr)
Inventor
Christian Viskov
Volker Laux
Pierre Mourier
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of TNSN06025A1 publication Critical patent/TNSN06025A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des mélanges d'oligosaccharides dérivés d'héparine ayant un poids moléculaire moyen de 1800 & ocirc 2400 Daltons, caractérisés par une forte activité aXa et une absence d'activité aIIa, leur procédé de préparation et les compositions pharmaceutiques les contenant.
TNP2006000025A 2003-07-24 2006-01-23 Mélanges d'oligosaccharides dérivés d'heparine, leur préparation et les compositions pharmaceutiques les contenant TNSN06025A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0309041A FR2857971B1 (en) 2003-07-24 2003-07-24 MIXTURES OF HEPARIN DERIVED OLIGOSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PCT/FR2004/001943 WO2005010051A2 (en) 2003-07-24 2004-07-22 Heparin-derived oligosaccharide mixtures, preparation thereof and pharmaceutical compositions containing said mixtures

Publications (1)

Publication Number Publication Date
TNSN06025A1 true TNSN06025A1 (en) 2007-10-03

Family

ID=33561051

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000025A TNSN06025A1 (en) 2003-07-24 2006-01-23 Mélanges d'oligosaccharides dérivés d'heparine, leur préparation et les compositions pharmaceutiques les contenant

Country Status (39)

Country Link
EP (1) EP1651677B1 (en)
JP (1) JP4865552B2 (en)
KR (1) KR101125517B1 (en)
CN (1) CN1852926B (en)
AR (1) AR045917A1 (en)
AT (1) ATE487741T1 (en)
AU (1) AU2004259111B2 (en)
BR (1) BRPI0412850A (en)
CA (1) CA2533555A1 (en)
CR (1) CR8201A (en)
CY (1) CY1111165T1 (en)
DE (1) DE602004030015D1 (en)
DK (1) DK1651677T3 (en)
EC (1) ECSP066305A (en)
ES (1) ES2355827T3 (en)
FR (1) FR2857971B1 (en)
GT (1) GT200400145A (en)
HN (1) HN2004000250A (en)
IL (1) IL173206A (en)
MA (1) MA27928A1 (en)
ME (1) MEP11608A (en)
MX (1) MXPA06000336A (en)
MY (1) MY136769A (en)
NO (1) NO20060821L (en)
NZ (1) NZ544717A (en)
OA (1) OA13197A (en)
PA (1) PA8606801A1 (en)
PE (1) PE20050246A1 (en)
PL (1) PL1651677T3 (en)
PT (1) PT1651677E (en)
RS (1) RS20060044A (en)
RU (1) RU2346005C2 (en)
SI (1) SI1651677T1 (en)
TN (1) TNSN06025A1 (en)
TW (1) TWI369208B (en)
UA (1) UA89356C2 (en)
UY (1) UY28435A1 (en)
WO (1) WO2005010051A2 (en)
ZA (1) ZA200600657B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589145B2 (en) 2004-04-15 2009-09-15 Exxonmobil Chemical Patents Inc. Syndiotactic rich polyolefins
EP2447285A3 (en) * 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
CN101711771B (en) * 2008-10-07 2015-12-09 上海喜恩医药科技发展有限公司 A kind of polysaccharide mixture of heparin derivative and method for making thereof and pharmaceutical composition
DK3144325T3 (en) * 2010-09-14 2021-01-25 Univ Miyazaki HIGH PURITY HEPARIN AND ITS MANUFACTURING PROCEDURE
WO2012072799A1 (en) 2010-12-02 2012-06-07 Aventis Pharma S.A. New methods for the in vitro measurement of the biological activity of an ultra low molecular weight heparin sample
CN102558392A (en) * 2010-12-14 2012-07-11 王芃 Preparation method of high-FXa-resistant low-FIIa-resistant low-molecular heparin sodium
CN102816255B (en) * 2011-06-10 2015-11-25 王芃 A kind of preparation method of ultra-low molecular heparin sodium
EP2980103B1 (en) 2013-03-26 2020-11-04 Jiuzhitang Co., Ltd. Low molecular weight glycosaminoglycan derivative, pharmaceutical composition thereof, preparation method therefor and use thereof
CN103864959A (en) * 2014-04-03 2014-06-18 中国药科大学 Application of heparin oligosaccharide dp12 in atherosclerosis resistance
RU2639574C2 (en) * 2016-05-23 2017-12-21 Алексей Георгиевич Александров Process for low molecular weight heparin preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
FR2504928A1 (en) * 1981-04-29 1982-11-05 Choay Sa SHORT CHAIN OLIGOSACCHARIDES HAVING BIOLOGICAL PROPERTIES, PREPARATION THEREOF AND APPLICATIONS THEREOF AS MEDICAMENTS
FR2669932B1 (en) * 1990-12-03 1994-07-01 Sanofi Sa NOVEL HEPAROSANE-N, O-SULFATE, ITS PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
IT1284143B1 (en) * 1996-09-06 1998-05-08 Istituto Scient Di Chimica E B SEMI-SYNTHETIC HEPARANSULPHATES WITH HIGH ANTIMETASTIC ACTIVITY AND REDUCED HEMORRAGIC RISK
AU7753898A (en) * 1997-06-06 1998-12-21 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
ES2161615B1 (en) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa COMPOSITIONS OF HEPARINS OF VERY LOW MOLECULAR WEIGHT.
JP4897991B2 (en) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ Ultra low molecular weight heparin composition
FR2800074B1 (en) * 1999-10-22 2001-12-21 Aventis Pharma Sa NOVEL OLIGOSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP4585072B2 (en) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 Heparin depolymerization method, depolymerized heparin, derivatives thereof and pharmaceutical composition
FR2807043B1 (en) * 2000-03-28 2002-11-22 Aventis Pharma Sa PHARMACEUTICAL COMPOSITION CONTAINING OLIGOSACCHARIDES, NEW OLIGOSACCHARIDES AND THEIR PREPARATION
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
FR2811992B1 (en) * 2000-07-21 2003-07-04 Aventis Pharma Sa MIXTURES OF HEPARIN-DERIVED POLYSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2458852A1 (en) * 2001-08-28 2003-03-06 Leo Pharma A/S Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate
FR2845686B1 (en) * 2002-10-10 2013-08-30 Aventis Pharma Sa MIXTURES OF HEPARIN-DERIVED POLYSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
EP1651677A2 (en) 2006-05-03
MXPA06000336A (en) 2006-03-30
TW200522970A (en) 2005-07-16
KR20060059974A (en) 2006-06-02
JP2006528614A (en) 2006-12-21
IL173206A (en) 2010-11-30
PE20050246A1 (en) 2005-06-02
NZ544717A (en) 2009-09-25
SI1651677T1 (en) 2011-03-31
GT200400145A (en) 2005-03-16
AU2004259111A1 (en) 2005-02-03
AR045917A1 (en) 2005-11-16
RU2006105384A (en) 2007-09-10
UA89356C2 (en) 2010-01-25
CN1852926A (en) 2006-10-25
ES2355827T3 (en) 2011-03-31
CY1111165T1 (en) 2015-06-11
DE602004030015D1 (en) 2010-12-23
CN1852926B (en) 2010-05-12
WO2005010051A3 (en) 2005-06-16
PT1651677E (en) 2011-02-08
ATE487741T1 (en) 2010-11-15
AU2004259111B2 (en) 2009-06-11
KR101125517B1 (en) 2012-03-23
ECSP066305A (en) 2006-07-28
IL173206A0 (en) 2006-06-11
ZA200600657B (en) 2007-05-30
PA8606801A1 (en) 2005-02-04
DK1651677T3 (en) 2011-02-28
RU2346005C2 (en) 2009-02-10
CR8201A (en) 2006-09-22
MEP11608A (en) 2010-06-10
JP4865552B2 (en) 2012-02-01
BRPI0412850A (en) 2006-10-03
WO2005010051A2 (en) 2005-02-03
PL1651677T3 (en) 2011-04-29
TWI369208B (en) 2012-08-01
FR2857971B1 (en) 2005-08-26
CA2533555A1 (en) 2005-02-03
NO20060821L (en) 2006-04-20
HK1094806A1 (en) 2007-04-13
RS20060044A (en) 2008-06-05
EP1651677B1 (en) 2010-11-10
MA27928A1 (en) 2006-06-01
UY28435A1 (en) 2005-02-28
HN2004000250A (en) 2006-06-29
OA13197A (en) 2006-12-13
MY136769A (en) 2008-11-28
FR2857971A1 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
TNSN06025A1 (en) Mélanges d'oligosaccharides dérivés d'heparine, leur préparation et les compositions pharmaceutiques les contenant
BG104780A (en) Inhibitors of phospholipase enzymes
EA200300580A1 (en) LACTAM CONNECTIONS
WO2005016235A3 (en) Combined use of impdh inhibitors with toll-like receptor agonists
MA30359B1 (en) PROLONGED RELEASE PHARMACEUTICAL COMPOSITION BASED ON A RELEASE SYSTEM COMPRISING AN ACID-SOLUBLE POLYMER AND A PH-DEPENDENT POLYMER
WO1998038984A3 (en) Formulations for hydrophobic pharmaceutical agents
YU38801A (en) Azabicycloalkanes as ccr5 modulators
UA85993C2 (en) Conjugate of a bacterial superantigen and antibody moiety, pharmaceutical composition containing thereof and method for treatment of cancer in mammals
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
EP1649849A3 (en) Compositions for the treatment of Parkinson's disease containing a CB1 receptor antagonist and a product that activates the dopaminergic neurotransmission in the brain.
MY157377A (en) Ophthalmic composition
ATE466014T1 (en) SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS
AU2002305099A1 (en) Fatty alcohol drug conjugates
HRP20020330B1 (en)
PL351593A1 (en) Substantially oil−free cyclosporin compositions
PT1358177E (en) TREATMENT OF AFFECTIVE DISORDERS THROUGH THE COMBINED ACTION OF AN AGNIST OF THE NICOTYNIC RECIPIENT AND A MANOAMINERGIC SUBSTANCE
DZ3166A1 (en) Purine derivatives, process for their preparation, and pharmaceutical compositions containing them.
YU67900A (en) Succinamide inhibitors of interleukin-1beta converting enzyme
PL1608344T3 (en) Oral formulations of cladribine
MY137965A (en) Semi-solid formulations for the oral administrations of taxoids
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
WO2003000199A3 (en) Ilt3 and ilt4-related compositions and methods
WO2002056010A3 (en) Methods for the treatment of ibs
AU4925200A (en) Oral composition containing perlite
MXPA04001976A (en) Modified human growth hormone.